Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06315491 · ClinicalTrials.gov registry record · Phase 2
A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
A Phase 2 study of Platinum-resistant Ovarian Cancer and Refractory Ovarian Carcinoma, sponsored by Cybrexa Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 17
- Study locations
NCT06315491 is a Phase 2 study of Platinum-resistant Ovarian Cancer and Refractory Ovarian Carcinoma that is actively recruiting participants, run by Cybrexa Therapeutics. The registered enrollment target is 40 participants, below the 184-participant average among 17 other Platinum-resistant Ovarian Cancer trials with a reported enrollment target (78% lower). The trial reports 17 study locations across 13 states.
The verdict
NCT06315491, a Phase 2 study of Platinum-resistant Ovarian Cancer and Refractory Ovarian Carcinoma, is actively recruiting participants, sponsored by Cybrexa Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg/m2 every 21 days or 100 mg/m2 every 21 days.
Conditions Studied
Interventions
- DRUG CBX-12
Study Locations (17)
Arizona
- Honor Health - Scottsdale
- Arizona Oncology Associates - Tucson
Florida
- D&H Cancer Research Center - Margate
- South Florida Gynecology - Tampa
New York
- Pci Nyu Langone Health - New York
- Albert Einstein College of Medicine Montefiore Medical - New York
Texas
- Mary Crowley Cancer Research - Dallas
- Texas Oncology- Gulf Coast - The Woodlands
California
- Usc Norris Comprehensive Cancer Center - Los Angeles
Connecticut
- Yale University School of Medicine - New Haven
Indiana
- Northwest Cancer Centers - Dyer
Kentucky
- Norton Cancer Institute - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-09-25 |
| Est. Completion | 2025-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06315491
The ClinicalTrials.gov registry entry for NCT06315491 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 184-participant average among 17 other Platinum-resistant Ovarian Cancer trials with a reported enrollment target (78% lower). The listed sponsor is Cybrexa Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Platinum-resistant Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which CBX-12 is the first listed.
NCT06315491 reports 17 study locations spanning 13 distinct geographic areas - top geographies include Arizona, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT06315491 about?
NCT06315491 is a clinical study titled "A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer". The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg/m2 every 21 days or 100 mg/m2 every 21 days.
What is the current status of trial NCT06315491?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2024-09-25. Estimated completion is 2025-10.
What conditions does trial NCT06315491 study?
This clinical trial studies the following conditions: Platinum-resistant Ovarian Cancer, Refractory Ovarian Carcinoma.
What interventions are being tested in trial NCT06315491?
The interventions under investigation include: CBX-12 (DRUG).
Who is sponsoring clinical trial NCT06315491?
This trial is sponsored by Cybrexa Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06315491 being conducted?
This trial has 17 study locations across Arizona, California, Connecticut, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Platinum-resistant Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
RECRUITING · Phase 2
-
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer
RECRUITING · Phase 2
-
Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)
ACTIVE NOT RECRUITING · Phase 2
-
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
RECRUITING · Phase 1
-
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
RECRUITING · Phase 1
-
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.